

ASX ANNOUNCEMENT

19 September 2022

Anteris presents preliminary results for the first-time demonstrating restoration of normal pre-disease flow when compared to other TAVR's and SAVR's at 6 months

Brisbane, Australia and Boston Massachusetts, USA, Anteris Technologies Ltd (**Anteris** or the **Company**) (ASX: AVR) presents preliminary results demonstrating for the first-time restoration of normal pre-disease blood flow after aortic valve replacement at Transcatheter Cardiovascular Therapeutics (TCT) conference, the world's foremost meeting of interventional cardiologists.

In a study of 22 patients comparing valve flow amongst current aortic valve replacement technologies, Anteris demonstrated no significant difference to the normal healthy aortic valve's flow with DurAVR™ THV. When current generation TAVR (transcatheter aortic valve replacement) and SAVR (surgical aortic valve replacement) valves were compared to the healthy aortic valve, both groups demonstrated statistically significant worse flow.

"This exciting data continues to demonstrate that by shaping the leaflets to mimic the native aortic valve, not only do we achieve superior haemodynamic performance but also restore normal laminar flow which is now demonstrated for the first time", commented Dr Chris Meduri, Anteris CMO.

"Although preliminary, this data is remarkable and encouraging because it depicts a valve prosthesis, DurAVR™ THV, providing flow dynamics equal to that of a typical healthy native valve and is superior to current generation TAVR and SAVR haemodynamics", commented CEO Wayne Paterson.

END

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



Authorisation and Additional information

This announcement was authorised by Mr. Wayne Paterson, Chief Executive Officer.

For more information:

Deanne Curry

GRACosway

E: investors@anteristech.com

M: +61 414 388 997

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

LinkedIn: <https://www.linkedin.com/company/anteristech>